TY - JOUR T1 - Quantitative proteomics of coeliac gut during 14-day gluten challenge: low-level baseline inflammation despite clinical and histological normality predicts subsequent response JF - medRxiv DO - 10.1101/2020.05.04.20090977 SP - 2020.05.04.20090977 AU - Jorunn Stamnaes AU - Daniel Stray AU - Maria Stensland AU - Vikas K. Sarna AU - Tuula A. Nyman AU - Knut E. A. Lundin AU - Ludvig M. Sollid Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090977.abstract N2 - Objective To shed light on gut mucosa processes provoked by gluten exposure in coeliac disease, we performed a quantitative proteomic analysis of duodenal tissue from well-treated coeliac patients before and after gluten challenge.Design We extracted and digested proteins from formalin-fixed paraffin-embedded tissue of 19 coeliac disease patients who had been challenged orally with gluten for 14 days. Protein identification and quantification was done by label-free quantitative mass spectrometry-based proteomics from total tissue and from laser capture microdissected epithelial cell layer. Proteomics data were compared with clinical, serological and histological data.Results At baseline, all patients were in clinical and mucosal remission (Marsh 0-1) except one (Marsh 3). After challenge, five patients reached Marsh 3 scores. Proteome analysis categorised these five and additionally two patients as responders. Already at baseline, responder patients differed from the remaining patients in their gut tissue protein composition with altered levels of inflammatory and enterocyte function proteins – the same proteins that changed upon gluten challenge. Patients classified as responders from the proteomic analysis also differed from the remaining patients at baseline, with mild crypt hyperplasia and a slight increase in blood inflammatory parameters and gluten specific CD4+ T-cell frequencies.Conclusion Despite clinical and histological remission, coeliac disease patients that develop a mucosal response after 14-day gluten challenge have already at baseline altered protein compositions of their gut tissue with signs of ongoing inflammation. Thus, apparently well-treated coeliac disease is frequently not fully quiescent with presence of low-grade anti-gluten immunity in gut mucosa.Competing Interest StatementKEAL has privately or via his employer been consultant during the two last years for Chugai Pharmaceutical, Bioniz Therapeutics, Immusant Therapeutics, Interexon Actobiotics, Amyra Biotech AG and Dr. Falk Pharma GMBH. LMS has privately or via his employer been consultant during the two last years for Amagma Therapeutics, Chugai Pharmaceutical, Bioniz Therapeutics, Immusant Therapeutics, Interexon Actobiotics, UCB Biopharma, Merck and GSK. The other authors declare no conflicts of interest. Funding StatementThis work was supported by a grant from Stiftelsen Kristian Gerhard Jebsen (project SKGJ-MED-017) and by grants from South-Eastern Norway Regional Health Authority (projects 2013046 and 2016113).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProteomics raw data and affiliated data are available in proteomeXchange repository as reported in the materials and methods section. All data is available from the authors upon request. ER -